Depends on how good their cash flow management is, progress claims etc. Imo the writing is on the wall, otherwise why would have the outgoing shareholders sold at 0.6 x earnings.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025